Pfizer, Inc. (“Pfizer”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on March 24, 2017, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Roche
-
-
On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 9, 2016, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed three new petitions with the Patent Trial and Appeal Board (“PTAB”) on March 15, 2017 for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 16, 2016 for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 10, 2017, the PTAB published a decision terminating the proceedings in IPR2016-1693 and IPR2016-1694 because the parties have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 2, 2017, the PTAB issued a decision denying Celltrion, Inc.’s (“Celltrion”) request for inter partes review (“IPR”) of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on August 15, 2016 for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion’s Truxima (CT-P10, rituximab), a biosimilar to Rituxan® received approval from the European Commission on February 22, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]